Zevra Therapeutics (ZVRA) announced that its CFO and treasurer, R. LaDuane Clifton, will be stepping down from his position with the company, effective December 31 in order to pursue other professional opportunities. The company has initiated a search to identify its next chief financial officer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strategic Focus on Miplyffa Drives Buy Rating Amid Promising Growth Prospects
- Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth
- Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald
- Zevra Therapeutics price target lowered to $24 from $25 at Canaccord
- Zevra Therapeutics: Strong Q3 Performance and Promising Pipeline Justify Buy Rating